Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Transmedics Group Inc (NASDAQ: TMDX) was $69.11 for the day, down -0.32% from the previous closing price of $69.33. In other words, the price has decreased by -$0.32 from its previous closing price. On the day, 1.64 million shares were traded.
Ratios:
Our analysis of TMDX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.52 and its Current Ratio is at 8.30. In the meantime, Its Debt-to-Equity ratio is 2.27 whereas as Long-Term Debt/Eq ratio is at 2.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on December 17, 2024, Downgraded its rating to Neutral and sets its target price to $75 from $116 previously.
Oppenheimer reiterated its Outperform rating for the stock on October 29, 2024, while the target price for the stock was revised from $200 to $125.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’25 when Gordon Stephen bought 5,942 shares for $65.61 per share.
Khayal Tamer I sold 1,083 shares of TMDX for $86,694 on Jan 07 ’25. The Chief Commercial Officer now owns 20,843 shares after completing the transaction at $80.05 per share. On Dec 02 ’24, another insider, Khayal Tamer I, who serves as the Chief Commercial Officer of the company, sold 1,084 shares for $86.40 each. As a result, the insider received 93,658 and left with 20,843 shares of the company.
Valuation Measures:
As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 68.41, and their Forward P/E ratio for the next fiscal year is 30.73. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.27 while its Price-to-Book (P/B) ratio in mrq is 10.16.
Stock Price History:
Over the past 52 weeks, TMDX has reached a high of $177.37, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 2.11%, while the 200-Day Moving Average is calculated to be -39.89%.
Shares Statistics:
A total of 33.62M shares are outstanding, with a floating share count of 32.42M. Insiders hold about 3.68% of the company’s shares, while institutions hold 111.27% stake in the company.
Earnings Estimates
A comprehensive evaluation of Transmedics Group Inc (TMDX) is underway, with the input of 6.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.34, with high estimates of $0.41 and low estimates of $0.3.
Analysts are recommending an EPS of between $1.8 and $1.27 for the fiscal current year, implying an average EPS of $1.5. EPS for the following year is $2.24, with 6.0 analysts recommending between $2.5 and $1.94.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $130.3M to a low estimate of $115.43M. As of the current estimate, Transmedics Group Inc’s year-ago sales were $96.85MFor the next quarter, 7 analysts are estimating revenue of $132.51M. There is a high estimate of $134.7M for the next quarter, whereas the lowest estimate is $131M.
A total of 8 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $543.66M, while the lowest revenue estimate was $536.86M, resulting in an average revenue estimate of $540.2M. In the same quarter a year ago, actual revenue was $441.54MBased on 9 analysts’ estimates, the company’s revenue will be $648.52M in the next fiscal year. The high estimate is $684.07M and the low estimate is $625M.
